Medicine
Lonsurf 6.14 mg/15 mg tablet
Lonsurf 6.14 mg/15 mg tablet is a prescription medicine containing Tipiracil and Trifluridine for oral use, marketed by Taiho Pharmaceutical, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions are permitted from 15°C to…
Key facts
- Active ingredient (INN)
- Tipiracil and Trifluridine
- Brand
- Lonsurf
- Strength
- 6.14 mg/15 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 20 tablets, 40 tablets, 60 tablets
- Marketing authorisation holder
- Taiho Pharmaceutical
- Manufacturer
- Taiho Pharmaceutical
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions are permitted from 15°C to 30°C (59°F to 86°F). Follow applicable special handling and disposal procedures. 1 If stored outside of original bottle, discard after 30 days.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01BC59 Tipiracil and Trifluridine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 22 September 2015
- Identifiers
- RxCUI 1670311, 1670316, 1670322 +1DailyMed set ID f5beed22-d71d-4c0d-8dca-2c7317d65d85NDC 64842-1025Application NDA207981
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 20 tablet, film coated in 1 bottle | 64842-1025-1 | Taiho Pharmaceutical | 7 October 2015 |
| 40 tablet, film coated in 1 bottle | 64842-1025-2 | Taiho Pharmaceutical | 11 November 2015 |
| 60 tablet, film coated in 1 bottle | 64842-1025-3 | Taiho Pharmaceutical | 21 October 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Tipiracil and Trifluridine
Clinical summary
Tipiracil and Trifluridine is a fixed-dose combination of a nucleoside analog antiviral, a nucleoside metabolic inhibitor and a thymidine phosphorylase inhibitor. It is available as tablets for oral use. MedsAcross supplies Tipiracil and Trifluridine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Tipiracil and TrifluridineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- LONSURF prescribing information (Taiho Pharmaceutical) · U.S. National Library of Medicine, DailyMed
- Lonsurf: European public assessment report (EPAR) · European Medicines Agency
Need Lonsurf 6.14 mg/15 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.